CN105497924A - 一种b超检查用辅助显像的中药 - Google Patents
一种b超检查用辅助显像的中药 Download PDFInfo
- Publication number
- CN105497924A CN105497924A CN201610089923.8A CN201610089923A CN105497924A CN 105497924 A CN105497924 A CN 105497924A CN 201610089923 A CN201610089923 A CN 201610089923A CN 105497924 A CN105497924 A CN 105497924A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- rhizoma
- radix
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 30
- 238000002604 ultrasonography Methods 0.000 title claims abstract description 12
- 238000011161 development Methods 0.000 title abstract description 6
- 241000218176 Corydalis Species 0.000 claims abstract description 21
- 241000717739 Boswellia sacra Species 0.000 claims abstract description 13
- 239000004863 Frankincense Substances 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 7
- 244000293323 Cosmos caudatus Species 0.000 claims description 12
- 235000005956 Cosmos caudatus Nutrition 0.000 claims description 12
- 238000003745 diagnosis Methods 0.000 claims description 11
- 241001057584 Myrrha Species 0.000 claims description 10
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 10
- 241000180649 Panax notoginseng Species 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- 210000000582 semen Anatomy 0.000 claims description 8
- 230000000694 effects Effects 0.000 abstract description 22
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract description 5
- 235000013399 edible fruits Nutrition 0.000 abstract description 4
- 238000003759 clinical diagnosis Methods 0.000 abstract description 3
- 238000001514 detection method Methods 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 abstract description 2
- 241001278836 Agrimonia pilosa Species 0.000 abstract 1
- 235000000641 Agrimonia pilosa Nutrition 0.000 abstract 1
- 241001313855 Bletilla Species 0.000 abstract 1
- 241000759909 Camptotheca Species 0.000 abstract 1
- 240000007311 Commiphora myrrha Species 0.000 abstract 1
- 235000006965 Commiphora myrrha Nutrition 0.000 abstract 1
- 241000830532 Corydalis yanhusuo Species 0.000 abstract 1
- 244000163122 Curcuma domestica Species 0.000 abstract 1
- 241000906048 Loropetalum chinense Species 0.000 abstract 1
- 241000885743 Melastoma dodecandrum Species 0.000 abstract 1
- 235000007265 Myrrhis odorata Nutrition 0.000 abstract 1
- 240000002853 Nelumbo nucifera Species 0.000 abstract 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 abstract 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 abstract 1
- 235000004449 Panax japonicus var bipinnatifidus Nutrition 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 abstract 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 abstract 1
- 235000011613 Pinus brutia Nutrition 0.000 abstract 1
- 241000018646 Pinus brutia Species 0.000 abstract 1
- 240000002924 Platycladus orientalis Species 0.000 abstract 1
- 241000155589 Pteroxygonum Species 0.000 abstract 1
- 241000501113 Sargentodoxa cuneata Species 0.000 abstract 1
- 244000126014 Valeriana officinalis Species 0.000 abstract 1
- 235000013832 Valeriana officinalis Nutrition 0.000 abstract 1
- 235000003373 curcuma longa Nutrition 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 27
- 210000004369 blood Anatomy 0.000 description 26
- 210000004185 liver Anatomy 0.000 description 24
- 210000002784 stomach Anatomy 0.000 description 22
- 208000032843 Hemorrhage Diseases 0.000 description 20
- 230000017531 blood circulation Effects 0.000 description 16
- 208000002193 Pain Diseases 0.000 description 15
- 230000036407 pain Effects 0.000 description 15
- 230000000202 analgesic effect Effects 0.000 description 13
- 230000001276 controlling effect Effects 0.000 description 13
- 230000001737 promoting effect Effects 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- 230000000740 bleeding effect Effects 0.000 description 10
- 230000002439 hemostatic effect Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 239000000341 volatile oil Substances 0.000 description 9
- 208000014674 injury Diseases 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- AEQDJSLRWYMAQI-QGZVFWFLSA-N (13ar)-2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5h-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3C[C@@H]2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-QGZVFWFLSA-N 0.000 description 7
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 208000006820 Arthralgia Diseases 0.000 description 6
- 208000034507 Haematemesis Diseases 0.000 description 6
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 6
- 239000003513 alkali Substances 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- 206010027514 Metrorrhagia Diseases 0.000 description 5
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 5
- AEQDJSLRWYMAQI-UHFFFAOYSA-N Tetrahydropalmatine Natural products C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 5
- VRSRXLJTYQVOHC-YEJXKQKISA-N corydaline Chemical compound C=1([C@H]2[C@H]3C)C=C(OC)C(OC)=CC=1CCN2CC1=C3C=CC(OC)=C1OC VRSRXLJTYQVOHC-YEJXKQKISA-N 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 230000023597 hemostasis Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 229940090044 injection Drugs 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 206010022437 insomnia Diseases 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 235000013824 polyphenols Nutrition 0.000 description 5
- 230000002936 tranquilizing effect Effects 0.000 description 5
- 230000008736 traumatic injury Effects 0.000 description 5
- 201000000736 Amenorrhea Diseases 0.000 description 4
- 206010001928 Amenorrhoea Diseases 0.000 description 4
- 206010007247 Carbuncle Diseases 0.000 description 4
- 208000005171 Dysmenorrhea Diseases 0.000 description 4
- 206010013935 Dysmenorrhoea Diseases 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- 208000025747 Rheumatic disease Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 229930013930 alkaloid Natural products 0.000 description 4
- 231100000540 amenorrhea Toxicity 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- -1 contains turmerone Chemical class 0.000 description 4
- 208000010643 digestive system disease Diseases 0.000 description 4
- 208000001848 dysentery Diseases 0.000 description 4
- 208000018685 gastrointestinal system disease Diseases 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 210000002429 large intestine Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- GPTFURBXHJWNHR-UHFFFAOYSA-N protopine Chemical compound C1=C2C(=O)CC3=CC=C4OCOC4=C3CN(C)CCC2=CC2=C1OCO2 GPTFURBXHJWNHR-UHFFFAOYSA-N 0.000 description 4
- 230000000552 rheumatic effect Effects 0.000 description 4
- 229930182490 saponin Natural products 0.000 description 4
- 150000007949 saponins Chemical class 0.000 description 4
- 235000017709 saponins Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229920001864 tannin Polymers 0.000 description 4
- 235000018553 tannin Nutrition 0.000 description 4
- 239000001648 tannin Substances 0.000 description 4
- HAWSQZCWOQZXHI-FQEVSTJZSA-N 10-Hydroxycamptothecin Chemical compound C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-FQEVSTJZSA-N 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000036592 analgesia Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 230000001914 calming effect Effects 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 235000012754 curcumin Nutrition 0.000 description 3
- 239000004148 curcumin Substances 0.000 description 3
- 229940109262 curcumin Drugs 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 210000001198 duodenum Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 208000006750 hematuria Diseases 0.000 description 3
- 210000003097 mucus Anatomy 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 239000000932 sedative agent Substances 0.000 description 3
- 230000001624 sedative effect Effects 0.000 description 3
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- JLIDBLDQVAYHNE-YKALOCIXSA-N (+)-Abscisic acid Chemical compound OC(=O)/C=C(/C)\C=C\[C@@]1(O)C(C)=CC(=O)CC1(C)C JLIDBLDQVAYHNE-YKALOCIXSA-N 0.000 description 2
- KLFJSYOEEYWQMR-NRFANRHFSA-N 10-methoxycamptothecin Chemical compound C1=C(OC)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 KLFJSYOEEYWQMR-NRFANRHFSA-N 0.000 description 2
- KXJNTORVTHBKGW-UHFFFAOYSA-N 11-hydroxycamptothecin Natural products OC1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 KXJNTORVTHBKGW-UHFFFAOYSA-N 0.000 description 2
- NBGQZFQREPIKMG-UHFFFAOYSA-N 3beta-hydroxy-beta-boswellic acid Natural products C1CC(O)C(C)(C(O)=O)C2CCC3(C)C4(C)CCC5(C)CCC(C)C(C)C5C4=CCC3C21C NBGQZFQREPIKMG-UHFFFAOYSA-N 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- NBGQZFQREPIKMG-PONOSELZSA-N Boswellic acid Chemical compound C1C[C@@H](O)[C@](C)(C(O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C NBGQZFQREPIKMG-PONOSELZSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- VRSRXLJTYQVOHC-UHFFFAOYSA-N Corydaline Natural products CC1C2C=3C=C(OC)C(OC)=CC=3CCN2CC2=C1C=CC(OC)=C2OC VRSRXLJTYQVOHC-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000000616 Hemoptysis Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 208000008930 Low Back Pain Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- KKMPSGJPCCJYRV-UHFFFAOYSA-N Nitidine Chemical compound C1=C2C3=[N+](C)C=C4C=C(OC)C(OC)=CC4=C3C=CC2=CC2=C1OCO2 KKMPSGJPCCJYRV-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- GTRPODKMSBFDOI-UHFFFAOYSA-N Protopine Natural products CN1Cc2c3OCOc3ccc2C4C1Cc5cc6OCOc6cc5C4=O GTRPODKMSBFDOI-UHFFFAOYSA-N 0.000 description 2
- ZAALQOFZFANFTF-UHFFFAOYSA-N Pseudoprotipine Natural products C1=C2C(=O)CC3=CC=4OCOC=4C=C3CN(C)CCC2=CC2=C1OCO2 ZAALQOFZFANFTF-UHFFFAOYSA-N 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- KGEKLUUHTZCSIP-HOSYDEDBSA-N [(1s,4s,6r)-1,7,7-trimethyl-6-bicyclo[2.2.1]heptanyl] acetate Chemical compound C1C[C@]2(C)[C@H](OC(=O)C)C[C@H]1C2(C)C KGEKLUUHTZCSIP-HOSYDEDBSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000000702 anti-platelet effect Effects 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 210000002318 cardia Anatomy 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- LLEJIEBFSOEYIV-UHFFFAOYSA-N chelerythrine Chemical compound C1=C2OCOC2=CC2=CC=C3C4=CC=C(OC)C(OC)=C4C=[N+](C)C3=C21 LLEJIEBFSOEYIV-UHFFFAOYSA-N 0.000 description 2
- KXJNTORVTHBKGW-FQEVSTJZSA-N chembl39011 Chemical compound OC1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 KXJNTORVTHBKGW-FQEVSTJZSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- CHWPMFMUQATVNK-ARYYTZDLSA-N dihydrosporogen AO-1 Natural products O[C@H]1[C@]2(C(C)=C)O[C@@H]2[C@]2(C)[C@@H](C)[C@H](O)CCC2=C1 CHWPMFMUQATVNK-ARYYTZDLSA-N 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000001105 femoral artery Anatomy 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002213 flavones Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 210000001156 gastric mucosa Anatomy 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 230000002607 hemopoietic effect Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- FFWOKTFYGVYKIR-UHFFFAOYSA-N physcion Chemical compound C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1O FFWOKTFYGVYKIR-UHFFFAOYSA-N 0.000 description 2
- OISYIJRGMYJBRH-UHFFFAOYSA-N physcione Natural products COc1cc(O)c2C(=O)c3ccc(O)cc3C(=O)c2c1 OISYIJRGMYJBRH-UHFFFAOYSA-N 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 201000003068 rheumatic fever Diseases 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000002048 spasmolytic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000002435 venom Substances 0.000 description 2
- 210000001048 venom Anatomy 0.000 description 2
- 231100000611 venom Toxicity 0.000 description 2
- QWVUOVZJBNQSNS-UHFFFAOYSA-N (+-)-Tropan-3endo,6exo-diol Natural products C1C(O)CC2C(O)CC1N2C QWVUOVZJBNQSNS-UHFFFAOYSA-N 0.000 description 1
- MADYLZJCRKUBIK-RYGJVYDSSA-N (+/-)-Homochelidonine Chemical compound C([C@@H]1O)C2=CC=3OCOC=3C=C2[C@@H]2[C@H]1C1=CC=C(OC)C(OC)=C1CN2C MADYLZJCRKUBIK-RYGJVYDSSA-N 0.000 description 1
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- FFDULTAFAQRACT-NYYYOYJKSA-N (-)-syringaresinol O,O'-bis(beta-D-glucoside) Chemical compound COC1=CC([C@H]2[C@H]3[C@H]([C@@H](OC3)C=3C=C(OC)C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)=C(OC)C=3)CO2)=CC(OC)=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FFDULTAFAQRACT-NYYYOYJKSA-N 0.000 description 1
- UEPVWRDHSPMIAZ-IZTHOABVSA-N (1e,4z,6e)-5-hydroxy-7-(4-hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)hepta-1,4,6-trien-3-one Chemical compound C1=C(O)C(OC)=CC(\C=C\C(\O)=C\C(=O)\C=C\C=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-IZTHOABVSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- PCWTUTJLXXOQPR-GTUIBHIJSA-N (2S,3S,4R,5R,6S)-2-[[(2S,3R,4S,5S,6S)-6-[[(3R,4S,4aS,6aS,6bR,8R,8aR,14aS,14bR)-8-hydroxy-4,8a-bis(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,14a-dodecahydropicen-3-yl]oxy]-4,5-dihydroxy-3-[(2R,3S,4R,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound CC1(C)CC[C@@]2(CO)[C@H](O)C[C@@]3(C)C(C=C[C@H]4[C@]5(C)CC[C@@H](O[C@H]6O[C@@H](CO[C@H]7O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]7O)[C@H](O[C@H]7O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]7O)[C@@H](O)[C@@H]6O)[C@](C)(CO)[C@H]5CC[C@]34C)=C2C1 PCWTUTJLXXOQPR-GTUIBHIJSA-N 0.000 description 1
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 1
- IOIGOIPHPUCFOB-IMTBSYHQSA-N (6r,7s)-7-methyl-6,7-dihydro-5h-cyclopenta[c]pyridin-6-ol Chemical compound C1=NC=C2[C@H](C)[C@H](O)CC2=C1 IOIGOIPHPUCFOB-IMTBSYHQSA-N 0.000 description 1
- IYGYMKDQCDOMRE-ROUUACIJSA-N (6s)-6-[(5s)-6-methyl-7,8-dihydro-5h-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-6h-furo[3,4-g][1,3]benzodioxol-8-one Chemical compound O([C@@H]1[C@@H]2C3=CC=4OCOC=4C=C3CCN2C)C(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-ROUUACIJSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- LAOOXBLMIJHMFO-UHFFFAOYSA-N 1-[2-(diethylamino)ethylamino]-4-methylthioxanthen-9-one;hydron;chloride Chemical compound Cl.S1C2=CC=CC=C2C(=O)C2=C1C(C)=CC=C2NCCN(CC)CC LAOOXBLMIJHMFO-UHFFFAOYSA-N 0.000 description 1
- QLDAACVSUMUMOR-UHFFFAOYSA-M 2,3-dimethoxy-12-methyl-[1,3]benzodioxolo[5,6-c]phenanthridin-12-ium;chloride Chemical compound [Cl-].C1=C2C3=[N+](C)C=C4C=C(OC)C(OC)=CC4=C3C=CC2=CC2=C1OCO2 QLDAACVSUMUMOR-UHFFFAOYSA-M 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- PRUMMFPRJSEJJL-UHFFFAOYSA-N 4-morpholin-4-yl-3-nitroaniline Chemical compound [O-][N+](=O)C1=CC(N)=CC=C1N1CCOCC1 PRUMMFPRJSEJJL-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241000227129 Aconitum Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- LODGIKWNLDQZBM-UHFFFAOYSA-N Bulbocapnine Natural products C12=C3C4=C(O)C(OC)=CC=C4CC2N(C)CCC1=CC1=C3OCO1 LODGIKWNLDQZBM-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 240000008384 Capsicum annuum var. annuum Species 0.000 description 1
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 1
- 241000218645 Cedrus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- PCWTUTJLXXOQPR-UHFFFAOYSA-N Clinodiside A Natural products C=12CC(C)(C)CCC2(CO)C(O)CC(C2(CCC3C4(CO)C)C)(C)C=1C=CC2C3(C)CCC4OC(C(C(O)C1OC2C(C(O)C(O)C(CO)O2)O)O)OC1COC1OC(CO)C(O)C(O)C1O PCWTUTJLXXOQPR-UHFFFAOYSA-N 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- XDVZNDLANFJOQR-UHFFFAOYSA-N Coptisine Natural products O=Cc1c2OCOc2ccc1C=C3/NCCc4cc5OCOc5cc34 XDVZNDLANFJOQR-UHFFFAOYSA-N 0.000 description 1
- HJTVQHVGMGKONQ-LUZURFALSA-N Curcumin II Natural products C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=CC(O)=CC=2)=C1 HJTVQHVGMGKONQ-LUZURFALSA-N 0.000 description 1
- YIQVPNZGGSTDKI-UHFFFAOYSA-N D-bicucculine Natural products C12=CC=C3OCOC3=C2C(=O)OC1C1C2=CC(OCO3)=C3C=C2CCN1 YIQVPNZGGSTDKI-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- RATMHCJTVBHJSU-UHFFFAOYSA-N Dihydrochelerythrine Natural products C1=C2OCOC2=CC2=C(N(C)C(O)C=3C4=CC=C(C=3OC)OC)C4=CC=C21 RATMHCJTVBHJSU-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000010282 Emodin Substances 0.000 description 1
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- IOIGOIPHPUCFOB-UHFFFAOYSA-N Gentialutine Natural products C1=NC=C2C(C)C(O)CC2=C1 IOIGOIPHPUCFOB-UHFFFAOYSA-N 0.000 description 1
- 206010018276 Gingival bleeding Diseases 0.000 description 1
- 208000024283 Gingival haemorrhages Diseases 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000288140 Gruiformes Species 0.000 description 1
- 241001415959 Grus japonensis Species 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000004356 Hysteria Diseases 0.000 description 1
- MPYYVGIJHREDBO-UHFFFAOYSA-N Isovaleriansaeure-isobornylester Natural products C1CC2(C)C(OC(=O)CC(C)C)CC1C2(C)C MPYYVGIJHREDBO-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 206010050031 Muscle strain Diseases 0.000 description 1
- NEEQFPMRODQIKX-REOHCLBHSA-N N(3)-oxalyl-L-2,3-diaminopropionic acid Chemical compound OC(=O)[C@@H](N)CNC(=O)C(O)=O NEEQFPMRODQIKX-REOHCLBHSA-N 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- VJAXYZXLBFEJEG-UHFFFAOYSA-N Oxyterihanine Natural products C1=C2OCOC2=CC2=C(N(C)C(=O)C3=C4C=C(C(=C3)O)OC)C4=CC=C21 VJAXYZXLBFEJEG-UHFFFAOYSA-N 0.000 description 1
- PTPHDVKWAYIFRX-UHFFFAOYSA-N Palmatine Natural products C1C2=C(OC)C(OC)=CC=C2C=C2N1CCC1=C2C=C(OC)C(OC)=C1 PTPHDVKWAYIFRX-UHFFFAOYSA-N 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 208000018525 Postpartum Hemorrhage Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 1
- ILRCGYURZSFMEG-UHFFFAOYSA-N Salidroside Natural products OC1C(O)C(O)C(CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-UHFFFAOYSA-N 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010040849 Skin fissures Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 240000001949 Taraxacum officinale Species 0.000 description 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 241000223238 Trichophyton Species 0.000 description 1
- FZPYMZUVXJUAQA-ZDUSSCGKSA-N Turmerone Chemical compound CC(C)=CC(=O)C[C@H](C)C1=CCC(C)=CC1 FZPYMZUVXJUAQA-ZDUSSCGKSA-N 0.000 description 1
- FZPYMZUVXJUAQA-UHFFFAOYSA-N Turmerone Natural products CC(C)=CC(=O)CC(C)C1=CCC(C)=CC1 FZPYMZUVXJUAQA-UHFFFAOYSA-N 0.000 description 1
- 206010061577 Ulcer haemorrhage Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- ZRJLCVQCZVXUFB-QMMMGPOBSA-N Valerianine Chemical compound COCC1=CN=CC2=C1CC[C@@H]2C ZRJLCVQCZVXUFB-QMMMGPOBSA-N 0.000 description 1
- ZRJLCVQCZVXUFB-MRVPVSSYSA-N Valerianine Natural products O(Cc1c2c([C@H](C)CC2)cnc1)C ZRJLCVQCZVXUFB-MRVPVSSYSA-N 0.000 description 1
- BDIAUFOIMFAIPU-KVJIRVJXSA-N Valtratum Chemical compound C([C@]12[C@@H]3C(C(=CO[C@H]3OC(=O)CC(C)C)COC(C)=O)=C[C@@H]1OC(=O)CC(C)C)O2 BDIAUFOIMFAIPU-KVJIRVJXSA-N 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- LBRPLJCNRZUXLS-AZVRXDBZSA-N Vincosamide Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](C=C)[C@H](C[C@@H]2C3=C(C4=CC=CC=C4N3)CCN2C2=O)C2=CO1 LBRPLJCNRZUXLS-AZVRXDBZSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010051373 Wound haemorrhage Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- XOCANRBEOZQNAQ-KBPBESRZSA-N alpha-turmerone Natural products O=C(/C=C(\C)/C)C[C@H](C)[C@H]1C=CC(C)=CC1 XOCANRBEOZQNAQ-KBPBESRZSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003509 anti-fertility effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- JYTVKRNTTALBBZ-UHFFFAOYSA-N bis demethoxycurcumin Natural products C1=CC(O)=CC=C1C=CC(=O)CC(=O)C=CC1=CC=CC(O)=C1 JYTVKRNTTALBBZ-UHFFFAOYSA-N 0.000 description 1
- PREBVFJICNPEKM-YDWXAUTNSA-N bisdemethoxycurcumin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)CC(=O)\C=C\C1=CC=C(O)C=C1 PREBVFJICNPEKM-YDWXAUTNSA-N 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 229940119577 blood stop Drugs 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229940115397 bornyl acetate Drugs 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- LODGIKWNLDQZBM-LBPRGKRZSA-N bulbocapnine Chemical compound CN([C@H]1CC2=CC=C(C(=C2C2=C11)O)OC)CCC1=CC1=C2OCO1 LODGIKWNLDQZBM-LBPRGKRZSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 230000001595 contractor effect Effects 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- XYHOBCMEDLZUMP-UHFFFAOYSA-N coptisine Chemical compound C1=C2C=C(C3=C(C=C4OCOC4=C3)CC3)[N+]3=CC2=C2OCOC2=C1 XYHOBCMEDLZUMP-UHFFFAOYSA-N 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- IYGYMKDQCDOMRE-UHFFFAOYSA-N d-Bicucullin Natural products CN1CCC2=CC=3OCOC=3C=C2C1C1OC(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-UHFFFAOYSA-N 0.000 description 1
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 description 1
- QDFKFNAHVGPRBL-UHFFFAOYSA-N daucosterol Natural products CCC(CCC(C)C1CCC2C1CCC3C2(C)CC=C4CC(CCC34C)OC5OC(CO)C(O)C(O)C5O)C(C)C QDFKFNAHVGPRBL-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- NMRUIRRIQNAQEB-UHFFFAOYSA-N demethoxycurcumin Natural products OC(=CC(C=CC1=CC(=C(C=C1)O)OC)=O)C=CC1=CC=C(C=C1)O NMRUIRRIQNAQEB-UHFFFAOYSA-N 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- FCRACOPGPMPSHN-UHFFFAOYSA-N desoxyabscisic acid Natural products OC(=O)C=C(C)C=CC1C(C)=CC(=O)CC1(C)C FCRACOPGPMPSHN-UHFFFAOYSA-N 0.000 description 1
- YXAKCQIIROBKOP-UHFFFAOYSA-N di-p-hydroxycinnamoylmethane Natural products C=1C=C(O)C=CC=1C=CC(=O)C=C(O)C=CC1=CC=C(O)C=C1 YXAKCQIIROBKOP-UHFFFAOYSA-N 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 1
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000002575 gastroscopy Methods 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 description 1
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 1
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 description 1
- 229940046240 glucomannan Drugs 0.000 description 1
- 229940093181 glucose injection Drugs 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000000025 haemostatic effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 201000008659 immature cataract Diseases 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000037447 lactate metabolism Effects 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- USOSNFWVEWONDB-UHFFFAOYSA-N liriodendrin Natural products COc1cc(cc(OC)c1OC2OC(CO)C(O)C(O)C2O)C3OC(C)(C)C4C(OC(C)(C)C34)c5cc(OC)c(OC6OC(CO)C(O)C(O)C6O)c(OC)c5 USOSNFWVEWONDB-UHFFFAOYSA-N 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000008601 oleoresin Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- UEPVWRDHSPMIAZ-UHFFFAOYSA-N p-hydroxycinnamoyl feruloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(O)=CC(=O)C=CC=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-UHFFFAOYSA-N 0.000 description 1
- QUCQEUCGKKTEBI-UHFFFAOYSA-N palmatine Chemical compound COC1=CC=C2C=C(C3=C(C=C(C(=C3)OC)OC)CC3)[N+]3=CC2=C1OC QUCQEUCGKKTEBI-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 210000004203 pyloric antrum Anatomy 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- ILRCGYURZSFMEG-RQICVUQASA-N salidroside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-RQICVUQASA-N 0.000 description 1
- 230000001843 schistosomicidal effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000004799 sedative–hypnotic effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- VGTGOILROCHQGS-UHFFFAOYSA-N strictosidine lactam Natural products NC(CCC(=O)O)C(=O)OC1OC=C2C(CC3N(CCc4c3[nH]c5ccccc45)C2=O)C1C=C VGTGOILROCHQGS-UHFFFAOYSA-N 0.000 description 1
- KOWMJRJXZMEZLD-UHFFFAOYSA-N syringaresinol Chemical compound COC1=C(O)C(OC)=CC(C2C3C(C(OC3)C=3C=C(OC)C(O)=C(OC)C=3)CO2)=C1 KOWMJRJXZMEZLD-UHFFFAOYSA-N 0.000 description 1
- LVUPFEOCDSHRBL-UHFFFAOYSA-N syringaresinol Natural products COc1cccc(OC)c1C2OCC3C2COC3c4c(OC)cccc4OC LVUPFEOCDSHRBL-UHFFFAOYSA-N 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 229940068146 valepotriate Drugs 0.000 description 1
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 201000002282 venous insufficiency Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
Landscapes
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Acoustics & Sound (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及中药应用领域,特别公开了一种B超检查用辅助显像的中药。该一种B超检查用辅助显像的中药,以檵木叶,松花粉,断血流,红药子,藕节,地稔根,仙鹤草,白芨,没药,姜黄,大血藤,乳香,两面针,夏天无,延胡索,喜树果,合欢皮,缬草,柏子仁,珍珠,三七为原料;按照一定的重量配比制成。本发明一种B超检查用辅助显像的中药,其制作成本低,使用方便、安全无毒副作用,能够提高优良显影比例,提高检查准确性,使更多的胃肠疾病能够通过B超进行检查,为临床诊断提供了有力依据,而且制备工艺简单、实用。
Description
(一)技术领域
本发明涉及中药应用领域,特别涉及一种B超检查用辅助显像的中药。
(二)背景技术
目前,很多胃肠疾病的临床诊断主要依靠X线钡餐造影检查和胃镜检查,比如胃溃疡和十二指肠溃疡等,但此两项检查均有一定损伤和痛苦,存在一定的局限性,不易普及检查,尤其小儿、孕妇、年老体弱者不易接受,另无症状者也不易接受,导致一些误诊误治,甚至出现消化道穿孔或大出血才来诊治,耽误了治疗时机。B超检查虽然具有简便、安全、无创伤、无痛苦等优点,但由于其对部分胃肠疾病的诊断准确性差,一直无法被更多的胃肠疾病诊断所采用。
(三)发明内容
本发明为了弥补现有技术的不足,本发明人在总结临床实践的基础上,经反复试验,筛选药物,研究出一种配制简单、显像效果显著的一种B超检查用辅助显像的中药。
本发明是通过如下技术方案实现的:
一种B超检查用辅助显像的中药,由以下原料配置而成:檵木叶10-25份,松花粉10-23份,断血流11-21份,红药子13-26份,藕节11-23份,地稔根12-23份,仙鹤草10-23份,白芨10-25份,没药10-22份,姜黄10-23份,大血藤10-22份,乳香10-23份,两面针12-24份,夏天无12-23份,延胡索10-22份,喜树果11-23份,合欢皮12-23份,缬草10-23份,柏子仁12-23份,珍珠11-24份,三七10-23份。
其优选的各原料的药用性能为:檵木叶10份,松花粉10份,断血流11份,红药子13份,藕节11份,地稔根12份,仙鹤草10份,白芨10份,没药10-份,姜黄10份,大血藤10份,乳香10份,两面针12份,夏天无12份,延胡索10-份,喜树果11份,合欢皮12份,缬草10份,柏子仁12份,珍珠11份,三七10份。
本发明所用原料药的药理药效如下:
檵木叶:性凉,味苦、涩。归肝经、胃经、大肠经。清热解毒、收敛、止血。属止血药下属分类的收敛止血药。用治烧伤或烫伤、外伤出血、吐血、崩漏、腹泻。叶含鞣质、没食子酸及黄酮类成分;又据报道,从叶的黄酮类成分中分离出槲皮素。此外,叶尚含还原糖、苷类和酚性物质。有抗菌和宫缩作用,对心血管有影响。本品的鞣酸及其衍生物对蛋白质或血清有凝集沉淀作用,能收缩毛细血管及促进血液凝固。
松花粉:性温,味甘。归肝经、脾经。燥湿、收敛止血。属止血药下分类的收敛止血药。外用干掺或调敷。用量3~5克,调服或浸酒饮。用治黄水疮、皮肤湿疹、糜烂、婴儿尿布性皮炎、外伤出血。有抗病毒及收敛、止血作用。外敷止血效果良好。另具有增耐力、对抗疲劳的作用。
断血流:性凉,味苦、涩。归肝经。收敛止血。属止血药下属分类的收敛止血药。治疗崩漏,尿血,鼻衄,牙龈出血,创伤出血。全草含风轮菜皂甙A及薄公英赛-9,12,17-三烯3β,23-二醇等。
红药子:性微寒,味微苦、涩。归胃经、脾经、膀胱经、大肠经。止血,活血,养血,止痢,收敛止痛。属止血药下属分类的收敛止血药。外用研末或磨汁涂患处,适量。临床常用于治疗吐血、咯血、崩漏、产后出血、尿血、外伤出血、贫血、痢疾、腹泻、关节酸痛、毒蛇咬伤。块茎含缩合鞣质,尚含酚类、皂苷、蛋白质、糖类、粘液质等。药理实验表明:红药子的40%乙醇提取液和水煎液有抗菌作用。能显著缩短兔的凝血时间及出血时间。
藕节:性平,味甘、涩。归肝经、肺经、胃经。收敛止血,化瘀。属止血药下属分类的收敛止血药。用治胃中瘀热,吐血、咯血、鼻血、尿血、崩漏。含鞣质、天门冬素。鲜用能清热凉血,煅炭消瘀止血,收敛作用较强,能缩短出血时间。
地稔根:性平,味微酸、涩。归肺经、脾经、肝经。活血通络、收敛止血。属止血药分类下的收敛止血药。用治风湿痹痛、腰腿痛、产后腹痛、崩漏带下、外伤出血。含酚类、鞣质、氨基酸及糖类。
仙鹤草:性平,味苦、涩。归心经、肝经。收敛止血、截疟、止痢、解毒。属止血药下属分类的收敛止血药。用治咯血、吐血、崩漏下血、疟疾、血痢、脱力劳伤、痈肿疮毒、阴痒带下。含仙鹤草素、仙鹤内脂、鞣质、甾醇、有机酸、酚性成分、皂苷、黄酮苷等。仙鹤草素有止血、调整心率、增加细胞抵抗力、降低血糖和消炎等作用;冬芽含酚性物质鹤芽酚,冬芽及根有较强的驱绦虫作用,对金黄色葡萄球菌、大肠杆菌、绿脓杆菌、福氏痢疾杆菌、伤寒杆菌均有抑制作用。
白芨:性微寒,味苦、甘、涩。归肺经、肝经、胃经。收敛止血、消肿生肌。属止血药下属分类的收敛止血药。用治咳血吐血、肺结核咳血、溃疡病出血。外用适量。用治外伤出血、疮疡肿毒、皮肤皲裂。不宜与乌头类药材同用。含白及胶质(为由4份甘露糖和1份葡萄糖组成的葡配甘露聚糖)淀粉、葡萄糖、黏液质和蒽醌类化合物大黄素甲醚。提取物对实验动物有良好的止血作用,可能与所含胶状成分有关,作用原理可能为物理性的。2%白及葡萄糖注射液做腹腔注射试验,对DAB诱发的大鼠肝癌的发生有明显抑制作用。
没药:性平,味辛、苦。归心经、肝经、脾经。散瘀定痛,消肿生肌。属活血化瘀药下分类的活血止痛药。用于胸痹心痛,胃脘疼痛,痛经经闭,产后瘀阻,癥瘕腹痛,风湿痹痛,跌打损伤,痈肿疮疡。与其他含油树脂的物质相似,没药(一般用酊剂)有某些局部刺激作用,可用于口腔洗剂中,也可用于胃肠无力时以兴奋肠蠕动。水浸剂用试管稀释法,1∶2对堇色毛癣菌等皮肤真菌有抑制作用。所含挥发油对霉菌有轻度抑制作用。没药煎剂20mg/kg股动脉注射,可使麻醉狗股动脉血流量增加,血管阻力下降。
姜黄:性温,味苦、辛。归脾经、肝经。破血行气、通经止痛。属活血化瘀药下属分类的活血止痛药。用治心腹痞满胀痛、癥瘕、妇女血瘀经闭、产后瘀停腹痛、跌打损伤、痈肿等。主要含挥发油及酚性物质。挥发油已鉴定出51种成分,以萜类化合物为主,主要有姜黄酮、姜油烯等;酚性成分主要有姜黄素等。应用薄层一比色法测定姜黄素、,脱甲氧基姜黄素和双脱甲氧基姜黄素的含量,并应用薄层扫描法测定姜黄素的含量。药理研究表明,本品有保肝、利胆、抗菌、抗炎、抗肿瘤、抗艾滋病、抗生育、降血脂等作用。
大血藤:性平,味苦。归大肠经、肝经。清热解毒、活血祛风、止痛。属活血化瘀药下属分类的活血止痛药。用治肠痈腹痛、经闭痛经、风湿痹痛、跌扑肿痛。含大黄素、大黄素甲醚、胡萝卜苷、β-谷甾醇、硬脂酸、毛柳苷、鹅掌楸苷。动物实验表明,水提醇沉物可提高耐缺氧能力、减弱心缩力、减慢心率、减少心输出量、减轻心肌梗死和心肌缺血程度、改善心肌梗死所致心肌乳酸代谢紊乱,具直接扩张冠状动脉的作用,对胃肠道平滑肌具抑制作用,亦具降压、增加血液中cAMP和cGMP含量的作用。
乳香:性温,味辛、苦。归心经、脾经、肝经。调气活血、定痛、消肿、生肌。属活血化瘀药下分类的活血止痛药。用治气血瘀滞、心腹疼痛、痈疮肿毒、跌打损伤、风湿痹痛、痛经、产后瘀血刺痛。临床还用于治疗急性阑尾炎。含树脂60%~70%、树胶27%~35%、挥发油3%~8%。树脂主要成分为游离a,B.乳香脂酸、结合乳香脂酸等。挥发油为乳香镇痛的有效成分,主要为具镇痛作用的乙酸正辛酯,占挥发油总量的92.46%。以仪-蒎烯作指标成分,可将索马里乳香与埃塞俄比亚乳香及苏丹乳香鉴别开。
两面针:性平,味苦、辛。有小毒。归胃经、肝经。行气止痛、活血化瘀、祛风通络。属活血化瘀药下分类的活血止痛药。用治气滞血瘀引起的跌扑损伤、风湿痹痛、胃痛、牙痛、毒蛇咬伤;外治汤火烫伤。含两面针碱、白屈菜红碱、异崖椒定碱、氯化两面针碱、氧化两面针碱等生物碱类成分。两面针提取物腹腔注射,对小鼠醋酸扭体反应、K+透入及光热刺激法均有镇痛作用。还具抗菌作用。此外,具中枢镇静、解痉、抗癌作用。注射剂和结晶一8片剂,可治疗神经痛、头痛、腰腿痛、风湿性关节炎及胃肠、外伤痛、感冒头痛及小手术局部麻醉、止痛等。
夏天无:性温,味苦、微辛。归肝经。活血、通络、行气止痛。属活血化瘀药下属分类的活血止痛药。用量5~16克。用治中风偏瘫、小儿麻痹后遗症、坐骨神经痛、风湿性关节炎、跌打损伤、腰肌劳损等。含四氢巴马亭(即延胡索乙素)、原阿片碱、空褐鳞碱、藤荷包牡丹定碱、夏天无碱等,其总碱含量达0.98%。应用高效薄层色谱分离及薄层扫描定量,对夏天无的化学成分及含量进行比较,结果表明,其延胡索乙素含量最高。药理实验表明,本品有抗张血管、抗血小板聚集、镇痛、解痉等作用。夏天无注射液在临床上治疗高血压脑血管病、骨关节肌肉疾病及青年近视等,均见良效。
延胡索:性温,味辛、苦。归肝经、脾经。活血散瘀、理气止痛。属活血化瘀药下分类的活血止痛药。或入丸散,治疗全身各部气滞血瘀之痛、痛经、经闭、症瘕、产后瘀阻、跌扑损伤、疝气作痛。含20多种生物碱,如紫堇碱、原阿片碱、a-别隐品碱、黄连碱、巴马亭等。总碱的镇痛效价是吗啡的40%,总碱中以延胡索甲素、延胡素乙素、延胡素丑素的镇痛作用最为明显,其中延胡素乙素最强,延胡素丑素次之,延胡素甲素再次,较大用量对兔、犬、猴等均有镇静催眠作用,延胡索乙素有对抗中枢兴奋和增强中枢抑制作用;静注延胡素乙素可缩小脑梗塞范围、脑水肿及钙离子抑制。毒性:总碱LD50为2840毫克/千克,延胡素乙素LD50为146毫克/千克。
喜树果:性寒,味苦、涩。归脾经、胃经、肝经。抗癌,散结,破血化瘀。属活血化瘀药下分类的破血消癥药。主治各种肿瘤,用于原发性肝癌,对胃癌、头颈部腺源性皮癌、白血病、膀胱癌等恶性肿瘤等。也用于治疗血吸虫病引起的肝脾肿大。抗肿瘤;有抑制成纤维细胞增生作用;抗早孕;抑制疱疹病毒。过去多从根中提取喜树碱,近年来研究发现果实疗效最佳,毒性小,喜树碱和羟基喜树碱含量最高,采集方便,又不损伤植株,故目前商品多收购果实,作为提取分离喜树碱和羟基喜树碱的原料。目前多用喜树果的提取物制成酒浸膏注射液及水煎膏片剂使用,其疗效与喜树碱纯品相似,而副作用明显低于喜树碱纯品。含喜树碱、羟基喜树碱、去氧喜树碱、喜树次碱,尚含桦皮酸及喜果苷。从喜树果中还分离得11-羟基喜树碱、10-甲氧基喜树碱、脱落酸、丁香脂素和β-谷甾醇,其中11-羟基喜树碱、10-甲氧基喜树碱为新生物碱。喜树的根、茎干、皮、叶和果实一样均含喜树碱,均有抗癌作用。
合欢皮:性平,味甘。归心经、肝经、肺经。解郁安神、活血消肿。属安神药下属分类的养心安神药。用治心神不安、忧郁失眠、肺痈疮肿、跌打损伤。现代用治心神不安、忧郁失眠。
缬草:性平,味苦,微甘。归心经、肝经。具有宁心安神的功效。属安神药下属分类的养心安神药。临床多用于治疗神经衰弱、失眠和癔病及其情绪激动。根含挥发油0.5%~2%,油中含异戊酸龙脑酯(bornylisovalerate)、乙酸龙脑酯(bornylacetate)等。另含缬草碱(valerine)、缬草恰碱(chatinine)等生物碱类成分以及缬草素(valepotriatium)等。现代药理实验结果证实了缬草具有镇静安定及降温的作用。此外还证实缬草具有短暂的降压作用和保肝作用。
柏子仁:性平,味甘。归心经、肾经、大肠经。养心安神、止汗、润肠。属安神药下属分类的养心安神药。用治虚烦失眠、心悸怔忡、阴虚盗汗、肠燥便秘。种子含皂苷、脂肪油及挥发油。还含谷甾醇、柏木醇、红松内酯等化合物。
珍珠:性寒,味咸。归肝经、心经。平肝潜阳、定惊明目。属平肝息风药下属分类的平抑肝阳药。用治头痛眩晕、烦躁失眠、肝热目赤、肝虚目昏。主含碳酸钙92%以上,内层角壳蛋白水解后得甘氨酸、丙氨酸和亮氨酸等17种氨基酸。尚含铝、铜、铁、镁等多种无机元素。实验表明,其珍珠层粉具有抗溃疡作用,能显著促进大鼠醋酸性胃溃疡的愈合。珍珠层粉水解物能显著延迟实验大鼠白内障的形成,对初期白内障亦有明显疗效。珍珠层粉还具有抗氧化作用,冠心病患者连续服用1个月后,可使血清过氧化脂质明显降低。中老年人服用珍珠层粉2个月后,记忆力和运动能力有所改善,细胞免疫功能有所提高。
三七:性温,味甘、微苦。归肝经、胃经。散瘀止血、消肿定痛。属止血药下属分类的化瘀止血药。用治咯血、吐血、衄血、便血、崩漏、外伤出血、胸腹刺痛、跌扑肿痛。动物试验表明,人参皂苷Rg类对中枢神经有兴奋作用,而Rb类则有抑制作用,三七总皂苷可抑制血小板凝集,三七提取物有强心、降压、保肝、抗炎、降低血中胆固醇、免疫调节和抗病毒作用。总面言之,对血液及造血系统具有止血、抗血小板聚集及溶栓、溶血、造血等作用;对心血管系统具有抗心律失常、抗动脉粥样硬化、耐缺氧及抗休克、改善脑缺血等作用;对神经系统具有中枢神经抑制、镇痛等作用;可增强免疫功能,保护肝功能,抗肿瘤,延缓衰老,降血糖,抗炎,调节物质代谢,促进生长;毒性较低,长期用药基本无副反应。主要含人参皂苷Rg1、槲皮素、乙酸、丁香烯、人参皂苷Re、亮氨酸、β-谷固醇-D-葡萄糖苷、人参炔三醇、三七皂苷等12种单体皂苷及止血成分田七氨酸。另含挥发油及多种微量元素。
显影判断标准:
(1)优良:显像剂充盈良好,胃壁内无气泡和粘液干扰,胃粘膜面显示清晰,胃壁五层结构清晰可辨。
(2)一般:显像剂充盈良好,胃壁内有少量气泡和粘液干扰,粘膜面显示较清晰,胃壁五层结构尚清晰,但不影响检测。
(3)不良:胃腔内有大量气泡和粘液,粘膜面显示不清,胃壁层次无法辨认,影响检测。
显影情况统计如下:
例数 | 优良 | 一般 | 不良 |
135 | 127 | 7 | 1 |
(94%) | (5.1%) | (0.9%) |
本发明一种B超检查用辅助显像的中药,其制作成本低,使用方便、安全无毒副作用,能够提高优良显影比例,提高检查准确性,使更多的胃肠疾病能够通过B超进行检查,为临床诊断提供了有力依据,而且制备工艺简单、实用。
(四)具体实施方式
下面通过具体实施例对本发明进行进一步的阐述,应该明白的是,下述说明仅是为了解释本发明,并不对其内容进行限定。
实施例1:
取檵木叶10份,松花粉10份,断血流11份,红药子13份,藕节11份,地稔根12份,仙鹤草10份,白芨10份,没药10-份,姜黄10份,大血藤10份,乳香10份,两面针12份,夏天无12份,延胡索10-份,喜树果11份,合欢皮12份,缬草10份,柏子仁12份,珍珠11份,三七10份,以常规制药手法制成散剂分袋包装,密封保存即可。
实施例2:
取檵木叶25份,松花粉23份,断血流21份,红药子26份,藕节23份,地稔根23份,仙鹤草23份,白芨25份,没药22份,姜黄23份,大血藤22份,乳香23份,两面针24份,夏天无23份,延胡索22份,喜树果23份,合欢皮23份,缬草23份,柏子仁23份,珍珠24份,三七23份,以常规制药手法制成散剂分袋包装,密封保存即可。
实施例3:
取檵木叶16份,松花粉15份,断血流17份,红药子18份,藕节18份,地稔根16份,仙鹤草15份,白芨19份,没药16份,姜黄17份,大血藤16份,乳香16份,两面针19份,夏天无17份,延胡索17份,喜树果16份,合欢皮15份,缬草17份,柏子仁16份,珍珠19份,三七18份,以常规制药手法制成散剂分袋包装,密封保存即可。
检查方法:取本发明实施例1-3的散剂15-20克,加入40-50ml开水中溶解,稍凉适温后饮用,饮用后3-5分钟进行检查。检查体位:以平卧位和右侧卧位为主,辅以左侧卧位和半坐位;操作方法:按胃、十二指肠在腹部的体表投影,依次从贲门、胃底部、胃体部胃大小弯、胃角切迹、胃窦幽门管和十二指肠做连续完整扫查,力求将胃、十二指肠声像图全貌清晰显示,重点观察胃贲门、胃小弯、胃角、胃幽门管和十二指肠球部;仔细观察胃各部位,胃壁厚度、层次结构、蠕动及病变区域的声像特征,胃黏膜连续完整性等。
以上所述,仅是本发明的较佳实施例而已,并非是对本发明作其它形式的限制,任何熟悉本专业的技术人员可能利用上述揭示的技术内容加以变更或改型为等同变化的等效实施例。但是凡是未脱离本发明技术方案内容,依据本发明的技术实质对以上实施例所作的任何简单修改、等同变化与改型,仍属于本发明技术方案的保护范围。
Claims (3)
1.一种B超检查用辅助显像的中药,其特征为,由以下原料配置而成:檵木叶10-25份,松花粉10-23份,断血流11-21份,红药子13-26份,藕节11-23份,地稔根12-23份,仙鹤草10-23份,白芨10-25份,没药10-22份,姜黄10-23份,大血藤10-22份,乳香10-23份,两面针12-24份,夏天无12-23份,延胡索10-22份,喜树果11-23份,合欢皮12-23份,缬草10-23份,柏子仁12-23份,珍珠11-24份,三七10-23份。
2.根据权利要求1所述的一种B超检查用辅助显像的中药,其特征为,由以下原料配置而成:檵木叶10份,松花粉10份,断血流11份,红药子13份,藕节11份,地稔根12份,仙鹤草10份,白芨10份,没药10-份,姜黄10份,大血藤10份,乳香10份,两面针12份,夏天无12份,延胡索10-份,喜树果11份,合欢皮12份,缬草10份,柏子仁12份,珍珠11份,三七10份。
3.根据权利要求1所述的一种B超检查用辅助显像的中药,其特征为,所述中药为散剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610089923.8A CN105497924A (zh) | 2016-02-18 | 2016-02-18 | 一种b超检查用辅助显像的中药 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610089923.8A CN105497924A (zh) | 2016-02-18 | 2016-02-18 | 一种b超检查用辅助显像的中药 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105497924A true CN105497924A (zh) | 2016-04-20 |
Family
ID=55706469
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610089923.8A Pending CN105497924A (zh) | 2016-02-18 | 2016-02-18 | 一种b超检查用辅助显像的中药 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105497924A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110251694A (zh) * | 2019-07-15 | 2019-09-20 | 陕西中医药大学 | 一种胃肠超声造影剂及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102935242A (zh) * | 2012-11-16 | 2013-02-20 | 夏玉萍 | 一种超声图像诊断中药辅助显像制剂及其制备方法 |
CN104623291A (zh) * | 2015-01-14 | 2015-05-20 | 王伟 | 一种治疗消化性溃疡的中药 |
CN105106978A (zh) * | 2015-09-07 | 2015-12-02 | 孙凤香 | 一种超声检查辅助显像中药制剂及其制备方法 |
-
2016
- 2016-02-18 CN CN201610089923.8A patent/CN105497924A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102935242A (zh) * | 2012-11-16 | 2013-02-20 | 夏玉萍 | 一种超声图像诊断中药辅助显像制剂及其制备方法 |
CN104623291A (zh) * | 2015-01-14 | 2015-05-20 | 王伟 | 一种治疗消化性溃疡的中药 |
CN105106978A (zh) * | 2015-09-07 | 2015-12-02 | 孙凤香 | 一种超声检查辅助显像中药制剂及其制备方法 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110251694A (zh) * | 2019-07-15 | 2019-09-20 | 陕西中医药大学 | 一种胃肠超声造影剂及其制备方法 |
CN110251694B (zh) * | 2019-07-15 | 2022-08-12 | 陕西中医药大学 | 一种胃肠超声造影剂及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106804643A (zh) | 一种检验科用中药杀菌消毒液 | |
CN105288041A (zh) | 一种防治肾病综合征的中药制剂及制法 | |
CN101569739A (zh) | 一种治疗胆囊炎的中药组合物及其制备方法 | |
CN104998197A (zh) | 一种用于治疗肝癌的中药组合物 | |
CN105497924A (zh) | 一种b超检查用辅助显像的中药 | |
CN110538308B (zh) | 一种生发的中药组合物及其制备方法 | |
CN106421283A (zh) | 一种治疗皮肤疾病的中药药膏 | |
CN104984141A (zh) | 一种治疗便秘的方剂及其制备方法 | |
CN104800764A (zh) | 治疗肝癌的中药剂及制法 | |
CN104887950A (zh) | 一种治疗乳痈的中药组合物 | |
CN110742990A (zh) | 一种治疗非酒精性单纯性脂肪肝的中药组合物及制剂和应用 | |
CN104352802A (zh) | 治疗慢性痢疾的中药组合物及制备方法 | |
CN103386104B (zh) | 一种治疗丹毒的中药组合物及其制备方法 | |
CN103705856B (zh) | 用于预防放化疗急性放射反应的中药组合物 | |
CN107007697A (zh) | 一种治疗盆腔炎或前列腺炎的中药组合物及其制剂 | |
CN104225094A (zh) | 治疗贝赫切特综合征的中药制剂 | |
CN105287829A (zh) | 一种医治肾病综合征的中药组合物及制法 | |
CN104706866A (zh) | 一种治疗肠炎的中药制剂及制备方法 | |
CN104606638A (zh) | 一种治疗湿热型急性湿疹的药物及其制备方法 | |
CN104815267A (zh) | 治疗小儿食积的消食化积中药剂 | |
CN105287933A (zh) | 一种医治动脉硬化的健脾益气中药制剂及制法 | |
CN105169277A (zh) | 一种保肝利胆的栀子口服液及其制备方法 | |
CN104367942A (zh) | 一种治疗儿童痰热壅肺型大叶性肺炎的中药及制备方法 | |
CN111759948A (zh) | 一种修复胃肠黏膜的中药组合物及其制备方法和应用 | |
CN105560430A (zh) | 治疗慢性痢疾的活血止痢制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160420 |
|
RJ01 | Rejection of invention patent application after publication |